Click Here to Read More … A Mayo Clinic-led study, published in the American Society of Hematology (ASH) journal Blood found that CyBorD, a triple chemotherapy drug combination that has been successful in helping patients with the blood cancer multiple myeloma, also showed promise in improving the care for patients with the rare blood disease AL amyloidosis.
Mayo Clinic Research News and Discovery’s Edge

Visit www.KnowledgeofMedicine.com for additional resources for everything medicine